MANNITOL 10% (mannitol) by Pfizer is osmotic activity [moa]. First approved in 1967.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
Mannitol 10% is an osmotic diuretic administered by injection used to reduce intracranial pressure and manage acute renal failure. It works by creating an osmotic gradient that draws fluid from tissues into the vascular space, promoting diuresis and reducing cerebral edema. This is a foundational critical care agent with decades of clinical use.
As an aging legacy injectable with LOE approaching, the brand team is likely small and focused on maintaining stable hospital formulary relationships rather than growth initiatives.
Osmotic Activity
Osmotic Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma
A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy
A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
Worked on MANNITOL 10% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on mannitol 10% offers stability in a legacy, non-growth therapeutic area with minimal development risk but limited career acceleration. Roles center on maintaining market access, hospital relationships, and efficient supply chain management rather than innovation or launch activities.